# Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma

> **NCT02234115** · PHASE3 · COMPLETED · sponsor: **Foresee Pharmaceuticals Co., Ltd.** · enrollment: 137 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Leuprolide Mesylate

## Key facts

- **NCT ID:** NCT02234115
- **Lead sponsor:** Foresee Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2016-08-30
- **Final completion:** 2017-01-05
- **Target enrollment:** 137 (ACTUAL)
- **Last updated:** 2019-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02234115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02234115, "Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02234115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*